{'fraction_non_alphanumeric': 0.028503562945368172, 'fraction_numerical': 0.02494061757719715, 'mean_word_length': 4.9787234042553195, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Radio-oncological treatment possibilities in local recurrence of rectal carcinoma. An interdisciplinary comparison].

Local recurrences of rectal carcinomas are frequently associated with a considerable morbidity and a dismal prognosis. Surgical resection leads to long term tumor control in about 30 to 40%, but surgery can be offered to only 10 to 30% of the patients. Cytotoxic chemotherapy is able to induce local responses in 15 to 40% of the cases--similar figures as achieved by radiation therapy alone. A pilot study is presented using radiation therapy combined with the sensitizing agent razoxane (ICRF 159). There was an objective response rate of 62% and the median survival rose to 24 months (13 months with radiation therapy alone). These data compare almost to results seen in surgical series. However, they need confirmation.